For decades, advanced lung cancer was a quick death sentence. That’s no longer a given, thanks in part to the arrival of immunotherapy. If a medical meeting in Barcelona this week was any indication, more help could be on the... Read more »
The treatment landscape for lung cancer has shifted significantly over the past few years, and more changes could be on the way. At the World Conference on Lung Cancer in Barcelona this weekend a number of drug makers trotted out... Read more »
[Updated 8/26/19, 10:30am. See below.] Remember when the new wave of expensive cholesterol-lowering drugs—known as PCSK9 inhibitors—was supposed to give the healthcare system a financial heart attack?
Far from it. Four years after approval the two PCSK9 blockers... Read more »
Ford subsidiary Autonomic today announced a step forward in its drive to expand the online mobility hub it built to manage digital interactions among cars, drivers, fleets, service providers, and auto manufacturers—including Ford’s rivals.
We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7 billion in 2018, and Novartis reportedly... Read more »
Gene therapy has become one of the hottest fields in biomedicine, with two treatments approved in the US already and several more on the way. But surprise news this week regarding Zolgensma, the recently approved spinal muscular atrophy treatment, cast... Read more »
Plant genetics startup Inari, which is developing crop varieties that produce higher yields and use fewer resources, has raised $89 million to advance its research toward the US and international markets.
Corn, soybean, wheat, and tomatoes are the Cambridge, MA-based company’s... Read more »
Three years ago, the FDA made one of the most polarizing decisions in its history. It approved a drug for the rare genetic disease Duchenne muscular dystrophy on the slimmest of evidence, a watershed moment that caused a highly publicized rift... Read more »
What will the legacy be of Jeff Leiden, the longtime CEO of Vertex Pharmaceuticals?
Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written. He steered Vertex... Read more »
Bristol-Myers Squibb (NYSE: BMY) this afternoon revealed yet another setback for its cancer immunotherapy nivolumab (Opdivo) in lung cancer, boosting the outlook for rival Merck.
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
President of the Council for Economic Development (CED)
President, CEO, and Chairman of the Board of SciQuest
Professor at the University of North Carolina at Chapel Hill
Managing Partner at Pappas Ventures
CEO and co-founder of BoostSuite
Retired CEO of ShopperTrak RCT Corporation
CEO of the Marine Bio-Technologies Center of Innovation
Vice Provost and Director of the Innovation and Entrepreneurship Initiative at Duke University
CEO of G1 Therapeutics
Vice President, Carolinas HealthCare System